1 Dr Sunil Kumar, 2 Dr Deepak Kumar, 3 Dr Khushboo Kumari, 4 Dr Aaruni Rahul, 5 Dr Vishal Vaibhaw, 6 Dr Vinay Kumar Singh
1,2,4,5 Assistant Professor, Department of Emergency Medicine, AIIMS Patna, Bihar, India
3 Resident, Department of Microbiology, PMCH, Bihar, India
6 Senior Resident, Department of Emergency Medicine, AIIMS Patna, Bihar, India
ABSTRACT:
Background: Dyslipidemia is a significant risk factor for cardiovascular complications and renal damage in diabetic patients, particularly those with nephropathy. It exacerbates diabetic nephropathy (DN) progression through mechanisms such as oxidative stress and glomerulosclerosis.
Objectives: This study aimed to compare lipid abnormalities between diabetic patients with nephropathy and those without, assess correlations with glycemic control and urinary microalbumin, and evaluate dyslipidemia’s impact on renal function.
Methods: A cross-sectional study was conducted at Patna Medical College & Hospital involving 60 diabetic patients aged 20–60 years, divided into two groups: diabetic patients with nephropathy (Group A, n=30) and without nephropathy (Group B, n=30). Demographics, lipid profiles, glycemic parameters, and renal function were analyzed. Dyslipidemia prevalence was assessed, and statistical significance was determined using SPSS (p<0.05 considered significant).
Results: Dyslipidemia was more prevalent in the nephropathy group (73.3% vs. 46.7%, p=0.03), with significantly elevated cholesterol, triglycerides, LDL-C, and reduced HDL-C levels. Mean fasting glucose, postprandial glucose, and HbA1c levels were also higher in the nephropathy group (p<0.05).
Conclusion: Dyslipidemia is significantly more severe in diabetic patients with nephropathy, linked to poor glycemic control and renal dysfunction. Targeted lipid management strategies are essential to mitigate cardiovascular and renal risks in these patients.
KEYWORDS :
Dyslipidemia, Diabetic nephropathy, Glycemic control, Renal dysfunction.
REFERENCES :
1) Durrington PN. Hyperlipidaemia: diagnosis and management. London: Hodder Arnold; 2007.
2) Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003; 46:760–765.
3) Emerging Risk Factors Collaboration. Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375:2215–2222.
4) Emerging Risk Factors Collaboration. Seshasai SR, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364:829–841.
5) Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010; 362:800–811.
6) Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl (2011) 2013; 3:259-305.
7) Haffner S, M, Lehto S, Ronnemaa T, Pyoratak, Laukso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-34.
8) Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia: a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 1994;45: S125-31.
9) Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL; DCCT/EDIC Research Group. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int 2003; 64:817-28.
10) Suchitra MM, Sheshu Kumar M, Bitla AR, Madhusudhana Rao A, Alok S. Atherogenic dyslipidemia in diabetic nephropathy: lipoprotein (a), lipid ratios and atherogenic index. Int J Res Med Sci 2013; 1:455-9.
11) Jisieike-Onuigbo NN, Unuigbe EI, Kalu OA, Oguejiofor CO, Onuigbo PC. Prevalence of dyslipidemia among adult diabetic patients with overt diabetic nephropathy in Anambra state south-east Nigeria. Niger J Clin Pract 2011; 14:171-5.
12) Abdul-Ramman AN, Olufunsho F. Hyperlipidemia among Saudi diabetic patients-pattern and clinical characteristics. Ann Saudi Med 1995; 15:240-3.
13) Akbar DH. Hyperlipidemia in diabetic patients in Saudi Arabia. Diabetes International 2001; 1:17-8.
14) Jacobs DR Jr. Plasma lipid distributions in selected North American populations: The lipid research clinic program prevalence study. Lipid Research clinics Program Epidemiologic Committee. Circulation 1970; 60:427-39.
15) Agaba IE, Anteyi EA, Puepet FH, Omudu PA, Idoko JA. The clinical pattern of diabetic nephropathy in Type II diabetes mellitus in North Central Nigeria. J Med Tropics 2002; 4:10.
16) Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 1998; 13:2833-41.
17) Mangiti R, Deferari G, Di Mario U Giampietro O, Navalesi R, Nosadini R, et al. Arterial hypertension and microalbuminuria in IDDM: The Italian microalbuminuria study. Diabetologia 1994; 37:1015-24.
